TY - JOUR
T1 - Prolonged Treatment Interruption after Immunologic Response to Highly Active Antiretroviral Therapy
AU - Tarwater, Patrick M.
AU - Parish, Michelle
AU - Gallant, Joel E.
PY - 2003/12/1
Y1 - 2003/12/1
N2 - Duration of treatment interruption (TI) was investigated in 105 human immunodeficiency virus-infected patients whose antiretroviral therapy was interrupted with the intention to resume therapy on the basis of clinical or laboratory indicators. In a mixed cohort study, 57% of patients had not resumed therapy at the time of writing (median TI duration, 114 weeks); the most recent analysis of this group revealed a mean CD4 cell count of 500 cells/mm 3. Patients with lower CD4 cell counts at therapy initiation were more likely to resume therapy than were those with counts of >500 cells/mm3 (<200 cells/mm3 [relative hazard, 4.4]; and 200-350 cells/mm3 [relative hazard, 2.9]). Patients who met current United States Department of Health and Human Services criteria for starting therapy at the time of therapy initiation were 3 times more likely to resume therapy than were those who did not. Our results have implications for this TI strategy: there may be a subset of patients who can safely discontinue therapy for prolonged periods of time.
AB - Duration of treatment interruption (TI) was investigated in 105 human immunodeficiency virus-infected patients whose antiretroviral therapy was interrupted with the intention to resume therapy on the basis of clinical or laboratory indicators. In a mixed cohort study, 57% of patients had not resumed therapy at the time of writing (median TI duration, 114 weeks); the most recent analysis of this group revealed a mean CD4 cell count of 500 cells/mm 3. Patients with lower CD4 cell counts at therapy initiation were more likely to resume therapy than were those with counts of >500 cells/mm3 (<200 cells/mm3 [relative hazard, 4.4]; and 200-350 cells/mm3 [relative hazard, 2.9]). Patients who met current United States Department of Health and Human Services criteria for starting therapy at the time of therapy initiation were 3 times more likely to resume therapy than were those who did not. Our results have implications for this TI strategy: there may be a subset of patients who can safely discontinue therapy for prolonged periods of time.
UR - http://www.scopus.com/inward/record.url?scp=0345119074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0345119074&partnerID=8YFLogxK
U2 - 10.1086/379514
DO - 10.1086/379514
M3 - Article
C2 - 14614678
AN - SCOPUS:0345119074
SN - 1058-4838
VL - 37
SP - 1541
EP - 1548
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 11
ER -